Home › Niet-kleincellige longkanker › Illinois › Bloomington
Niet-kleincellige longkanker klinische studies in Bloomington, IL
11 studies voor Niet-kleincellige longkanker zoeken deelnemers op locaties in en rond Bloomington (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruterenFase 3
- Illinois CancerCare-Bloomington, Bloomington
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RekruterenFase 2
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RekruterenFase 3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mijl verwijderd
- Carle Cancer Institute Normal, Normal · 2 mijl verwijderd
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekruterenFase 3
- Illinois CancerCare- Bloomington, Bloomington
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruterenFase 3
- Illinois CancerCare - Bloomington, Bloomington
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RekruterenFase 2
- Illinois CancerCare-Bloomington, Bloomington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruterenFase 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2
- Illinois CancerCare-Bloomington, Bloomington
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2/3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mijl verwijderd
- Carle Cancer Institute Normal, Normal · 2 mijl verwijderd
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruterenObservatieonderzoek
- Illinois CancerCare-Bloomington, Bloomington
- Carle Cancer Institute Normal, Normal · 2 mijl verwijderd
Niet-kleincellige longkanker studies in andere steden
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH56 studies
- Washington, DC55 studies
Andere studies in Bloomington
- Longkanker9 studies
- Prostaatkanker7 studies
- Colorectale kanker7 studies
- Plaveiselcelcarcinoom van hoofd en hals6 studies
- Aldermeesklierkanker5 studies
- Melanoom5 studies
- Hypopharynxkanker5 studies
- Keelholtekanker5 studies
- Mondkanker5 studies
- Borstkanker5 studies
- Nierkanker (niercelcarcinoom)4 studies
- Acute myeloïde leukemie4 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.